Your browser doesn't support javascript.
Study protocol for the development and internal validation of Schizophrenia Prediction of Resistance to Treatment (SPIRIT): a clinical tool for predicting risk of treatment resistance to antipsychotics in first-episode schizophrenia.
Farooq, Saeed; Hattle, Miriam; Dazzan, Paola; Kingstone, Tom; Ajnakina, Olesya; Shiers, David; Nettis, Maria Antonietta; Lawrence, Andrew; Riley, Richard; van der Windt, Danielle.
  • Farooq S; Midlands Partnership NHS Foundation Trust, Stafford, Staffordshire, UK s.farooq@keele.ac.uk.
  • Hattle M; School of Medicine, Keele University, Keele, Staffordshire, UK.
  • Dazzan P; School of Medicine, Keele University, Keele, Staffordshire, UK.
  • Kingstone T; Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Ajnakina O; Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, University College London, London, UK.
  • Shiers D; Midlands Partnership NHS Foundation Trust, Stafford, Staffordshire, UK.
  • Nettis MA; School of Medicine, Keele University, Keele, Staffordshire, UK.
  • Lawrence A; Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Riley R; School of Medicine, Keele University, Keele, Staffordshire, UK.
  • van der Windt D; Psychosis Research Unit, Greater Manchester Mental Health NHS Trust, Manchester, UK.
BMJ Open ; 12(4): e056420, 2022 04 08.
Article in English | MEDLINE | ID: covidwho-1822070
ABSTRACT

INTRODUCTION:

Treatment-resistant schizophrenia (TRS) is associated with significant impairment of functioning and high treatment costs. Identification of patients at high risk of TRS at the time of their initial diagnosis may significantly improve clinical outcomes and minimise social and functional disability. We aim to develop a prognostic model for predicting the risk of developing TRS in patients with first-episode schizophrenia and to examine its potential utility and acceptability as a clinical decision tool. METHODS AND

ANALYSIS:

We will use two well-characterised longitudinal UK-based first-episode psychosis cohorts Aetiology and Ethnicity in Schizophrenia and Other Psychoses and Genetics and Psychosis for which data have been collected on sociodemographic and clinical characteristics. We will identify candidate predictors for the model based on current literature and stakeholder consultation. Model development will use all data, with the number of candidate predictors restricted according to available sample size and event rate. A model for predicting risk of TRS will be developed based on penalised regression, with missing data handled using multiple imputation. Internal validation will be undertaken via bootstrapping, obtaining optimism-adjusted estimates of the model's performance. The clinical utility of the model in terms of clinically relevant risk thresholds will be evaluated using net benefit and decision curves (comparative to competing strategies). Consultation with patients and clinical stakeholders will determine potential thresholds of risk for treatment decision-making. The acceptability of embedding the model as a clinical tool will be explored using qualitative focus groups with up to 20 clinicians in total from early intervention services. Clinicians will be recruited from services in Stafford and London with the focus groups being held via an online platform. ETHICS AND DISSEMINATION The development of the prognostic model will be based on anonymised data from existing cohorts, for which ethical approval is in place. Ethical approval has been obtained from Keele University for the qualitative focus groups within early intervention in psychosis services (ref MH-210174). Suitable processes are in place to obtain informed consent for National Health Service staff taking part in interviews or focus groups. A study information sheet with cover letter and consent form have been prepared and approved by the local Research Ethics Committee. Findings will be shared through peer-reviewed publications, conference presentations and social media. A lay summary will be published on collaborator websites.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psychotic Disorders / Schizophrenia / Antipsychotic Agents Type of study: Cohort study / Etiology study / Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-056420

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Psychotic Disorders / Schizophrenia / Antipsychotic Agents Type of study: Cohort study / Etiology study / Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2021-056420